Results 1 to 10 of about 58,504 (176)

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study

Annals of Oncology, 2007
David Cunningham, Tamas Hickish, Richard Osborne   +2 more
exaly  

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials

Annals of Oncology, 2004
David Cunningham, J -Y Douillard, E Mitry   +2 more
exaly  

St. John's Wort Interferes with Irinotecan

Ca-A Cancer Journal for Clinicians, 2002
exaly  

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma

Annals of Oncology, 2004
David Cunningham, Gina Brown, J S Waters
exaly  

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer

Annals of Oncology, 2007
Luigi Celio, Sara Pusceddu, Maria Di Bartolomeo   +2 more
exaly  

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction

Annals of Oncology, 2010
M Geissler, M P Ebert, P R Galle
exaly  

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

Annals of Oncology, 2006
L Fischer von Weikersthal, A Schmittel, K Schulze   +2 more
exaly  

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)

Annals of Oncology, 2008
L Collette, C Theodore, J M Kerst
exaly  

Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug

Acta Pharmaceutica Sinica B, 2023
Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite, SN-38. Unfortunately, the limited utility of irinotecan is attributed to its pH-dependent stability, short half-life and dose-limiting toxicity.
Jingkai Gu, John Paul Fawcett, Deqi Cai
exaly   +4 more sources

Irinotecan pharmacogenomics [PDF]

Pharmacogenomics, 2010
Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-threatening toxicities can occur from irinotecan treatment.
Marsh, Sharon, Janelle M Hoskins, Sharon Marsh, Hoskins, Janelle M   +3 more
core   +4 more sources